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Abstract
Macromolecule release from poly(D,L-lactide-co-glycolide) (PLGA) microspheres has been well-
characterized, and is a popular approach for delivering bioactive signals from tissue-engineered
scaffolds. However, the effect of some processing solvents, sterilization, and mineral
incorporation (when used in concert) on long-term release and bioactivity has seldom been
addressed. Understanding these effects is of significant importance for microsphere-based
scaffolds, given that these scaffolds are becoming increasingly more popular, yet growth factor
activity following sintering and/or sterilization is heretofore unknown. The current study evaluated
the 6-week release of transforming growth factor (TGF)-β3 and bone morphogenetic protein
(BMP)-2 from PLGA and PLGA/hydroxyapatite (HAp) microspheres following exposure to
ethanol (EtOH), dense phase carbon dioxide (CO2), or ethylene oxide (EtO). EtO was chosen
based on its common use in scaffold sterilization, whereas EtOH and CO2 were chosen given their
importance in sintering microspheres together to create scaffolds. Release supernatants were then
used in an accelerated cell stimulation study with human bone marrow stromal cells (hBMSCs)
with monitoring of gene expression for major chondrogenic and osteogenic markers. Results
indicated that in microspheres without HAp, EtOH exposure led to the greatest amount of
delivery, whilst those treated with CO2 delivered the least growth factor. In contrast, formulations
with HAp released almost half as much protein, regardless of EtOH or CO2 exposure. Notably,
EtO exposure was not found to significantly affect the amount of protein released. Cell stimulation
studies demonstrated that eluted protein samples performed similarly to positive controls in
PLGA-only formulations, and ambiguously in PLGA/HAp composites. In conclusion, the use of
EtOH, subcritical CO2, and EtO in microsphere-based scaffolds may have only slight adverse
effects, and possibly even desirable effects in some cases, on protein availability and bioactivity.
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1. INTRODUCTION
In many tissue engineering applications, a considerable fraction of regenerative efficacy
originates from physicochemical signals embedded within a scaffold. These signals can be
natural or material-based such as collagens, minerals, synthetic substrates, or small
molecules.[1, 2] Some applications, however, utilize the release of bioactive factors, such as
macromolecules. Vascular endothelial growth factors (VEGFs),[3, 4] glial-derived
neurotrophic factors (GDNFs),[5-7] insulin-like growth factors (IGFs),[8-10] BMPs,[11-15]
and TGFs[8, 9, 16-18] have become increasingly popular in tissue engineering, as these
stimulate angiogenesis, promote neural growth, increase biochemical production, and
initiate stem cell differentiation into bone and cartilage, respectively. Thus, ample effort is
placed on the determination of techniques to load and deliver said molecules the site of
action.
Popular delivery vehicles for macromolecules are PLGA nano- or microparticles, which can
be created by a number of methods.[19] These particles can be embedded within fibrous
matrices, hydrogels, or collagen networks.[20, 21] Some applications, however, use sphere-
shaped microparticles to create scaffolds constructed solely of the microspheres alone.
Microsphere-based scaffolds have been the focus of our technology that sinters
microspheres together using EtOH[22-25] or subcritical CO2.[26] The scaffolds can be
made into custom sizes and shapes[26] or incorporate nanoparticles to create nanocomposite
materials.[24] An advanced variation of this microsphere-based scaffold design utilized two
types of microspheres (loaded with either TGF-β or BMP-2) oriented in an opposing
continuous-gradient fashion.[22, 23] The regions provided regenerative signals for cartilage
and bone growth in a single seamless 3-D design.
Biochemical and histological results from in vitro[23] and in vivo[22, 27] studies utilizing
the dual-gradient design have provided supportive evidence of growth factor bioactivity, but
there remain many questions about protein delivery and bioactivity after being subjected to
processing conditions such as EtOH, CO2, or EtO. These treatments are of particular
importance because both EtOH and CO2 are used to sinter microspheres together into a
shape-specific scaffold (although others have used hydrogels to effectively encapsulate the
microspheres in lieu of creating a macroporous scaffold[28]), and EtO is used to sterilize the
scaffolds. In addition, the effect of mineral nanoparticle inclusion, which is intended to
facilitate osteo- induction/conduction[29-35] and provide “raw materials” for the
regenerating tissue, on protein delivery characteristics is unknown. Thus, an investigation on
the overall effect of scaffold fabrication procedures on cartilage- and bone-promoting
growth factor delivery and bioactivity is a critical step in refining the microsphere-based
scaffold design. With such knowledge, future iterations could potentially utilize mineral
incorporation in conjunction with bioactive factors, creating both material and signal
gradients.
The current study evaluated the general release characteristics of BMP-2 and TGF-β3 from
PLGA microspheres subjected either to EtO alone, EtO with EtOH, EtO with CO2, or EtOH
alone. In addition, BMP-2 was also loaded in PLGA/HAp composite microspheres and
exposed to the aforementioned conditions to elucidate the effects of minerals on protein
availability. Release supernatants from experimental groups were utilized in an accelerated
cell stimulation study with hBMSCs, after which gene expression of major chondrogenic
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and osteogenic markers was measured and compared to positive and negative control
treatments.
2. MATERIALS AND METHODS
2.1 Materials
PLGA copolymer (50:50 lactic acid : glycolic acid, acid end group, MW ~38,000 Da) of
intrinsic viscosity (i.v.) 0.34 dL/g was purchased from Lakeshore Biomaterials
(Birmingham, AL). Poly(vinyl alcohol) (PVA; 88% hydrolyzed, 25,000 Da) was obtained
from Polysciences, Inc. (Warrington, PA). Nanophase HAp (< 200 nm) and Pluronic F-127
(F-127) were purchased from Sigma Aldrich (St. Louis, MO). Recombinant human TGF-β3
and BMP-2 (E. coli derived) were purchased from Peprotech, Inc. (Rocky Hill, NJ).
hBMSCs from a single donor (29 year old, African American male) at P1, (i.e., plated once)
were purchased from StemCell Technologies (Vancouver, Canada). HAp was purchased
from Sigma Aldrich (St. Louis, MO).
2.2 Preparation of Microspheres
Three types of microsphere formulations were prepared: TGF-β3-loaded, BMP-2-loaded,
and BMP-2-loaded with 5% w/w HAp. To fabricate the microspheres, either TGF-β3 or
BMP-2 was reconstituted in 0.1% w/v bovine serum albumin (BSA) in phosphate buffered
saline (PBS) (both from Sigma Aldrich). The reconstituted protein solutions were
individually mixed with PLGA that was dissolved in dichloromethane (DCM) at 20% w/v,
with an oil:water ratio of 10:1. For the BMP-2 formulation with 5% w/w HAp, nanophase
HAp was added to the PLGA-protein-DCM solution such that the total solids (HAp +
PLGA) content was 20% w/v. A loading mass of 30 ng TGF-β3 or 60 ng BMP-2 per 1.0 mg
of solids (PLGA or PLGA-HAp) was used, which represented concentrations employed in
previous in vivo studies.[22] The final mixture was then sonicated over ice at 30%
amplitude for 20 seconds. Using PLGA-protein (or PLGA-protein-HAp) emulsions, uniform
protein-loaded PLGA microspheres were prepared using technology described in our
previous reports.[22, 24-26, 36] Briefly, using acoustic excitation produced by an ultrasonic
transducer, regular jet instabilities were created in the polymer stream that produced uniform
polymer droplets of ~250 μm. An annular carrier non-solvent stream (0.5% w/v PVA in DI
H2O) surrounding the droplets was produced using a nozzle coaxial to the needle. The
emanated polymer/carrier streams flowed into a beaker containing the non-solvent at 0.5%
w/v with an additional 1.25% w/v F-127 in DI H2O to prevent aggregation of the particles.
Incipient polymer droplets were stirred for 3-4 hours to allow solvent evaporation, which
were then filtered and rinsed with DI H2O to remove residual PVA, and stored at −20 °C
(Fig. 1A). Following 48 hours of lyophilization, the microspheres were subjected to
individual treatments.
2.3 Description of Experimental Groups
Microsphere formulations (TGF-β3-loaded, BMP-2-loaded, and BMP-2-loaded with 5% w/
w HAp) were each subjected to three different experimental conditions plus one control
(Table 1). The experimental conditions represented those imposed on the microspheres
during scaffold fabrication and sterilization: EtOH exposure alone, subcritical CO2 exposure
followed by EtO sterilization, and EtOH exposure followed by EtO sterilization. The
exposure time of EtOH, and pressure for CO2, was adjusted accordingly for each type of
microsphere (described below and in Table 1), based on what was required for proper
microsphere sintering.[23-26] A negative control group for each type of microsphere
formulation was also included, where only EtO exposure was performed.
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Approximately 20 mg of microspheres were loaded into 1.5 mL microcentrifuge tubes
(Fisher Scientific, Pittsburgh, PA). Then, 1.0 mL of EtOH (200 proof, obtained in-house)
was added to the tube. The samples were allowed to sit for 60 minutes, after which the
ethanol was decanted and the microspheres were lyophilized for 48 hours. For PLGA
microspheres containing 5% w/w HAp, EtOH exposure was performed for 90 minutes, as
previous investigations showed that sintering microspheres that contain nanoparticles
required longer durations than observed with pure PLGA.[24, 27]
2.5 Subcritical CO2 Exposure
Approximately 20 mg of microspheres were loaded into 1.5 mL microcentrifuge tubes
(Fisher Scientific). The tubes were placed in a custom pressure vessel with a maximum
pressure rating of 400 bar, as we described in a previous report.[26] Vessels were purged of
air and filled with CO2 at a rate of ~1 psi/sec until reaching 218 psi (~15 bar). The samples
were maintained at this pressure for 60 minutes, at which point the chamber was evacuated
at a rate of ~1 psi/sec using an automated back pressure regulator (Waters Technologies
Corporation; Palatine, IL). For PLGA microspheres containing 5% w/w HAp, the samples
were subjected to a pressure of 363 psi (~25 bar) for 60 minutes, and the chamber was
evacuated at a rate of ~1 psi/sec.
2.6 Ethylene Oxide Sterilization
After EtOH or subcritical CO2 exposure, microsphere tubes were loaded into a sterilization
chamber (Anproline AN74i, Anderson Sterilizers, Haw River, NC) and exposed to EtO for
12 hours, followed by a 2-hour ventilation stage. For one EtOH-treated group, EtO exposure
was omitted as noted above. This group was included to elucidate the effects of EtOH alone
on release characteristics, in the event that EtOH is considered in the future as both a
sintering and sterilizing agent. Another group was treated with just EtO, to evaluate the
effects of EtO sterilization alone, without sintering (control).
2.7 Measurement of Glass Transition Temperature
Glass transition temperatures (Tg) for PLGA and PLGA/Hap composite microspheres
subjected to various treatments were determined by differential scanning calorimetry
analysis (DSC, Q200, TA Instruments, USA). Samples (1-5 mg) were equilibrated at 0 °C
and purged with pure dry nitrogen at a flow rate of 40 ml/min. The samples were then
heated to 70 °C at 5 °C/min, after which they were cooled back to 0 °C at the same rate.
Afterward, the second heating cycle followed at a 5 °C/min temperature ramp speed to 70
°C. The Tg was obtained by calculating the onset, end, and inflection of the glass transition.
For the analysis, samples were crimped in standard aluminum pans. An empty pan, sealed in
the same way as the samples, was used as a reference.
2.8 Protein Release
Protein release was conducted as previously-described, with the exception of placing
samples in small tubes, as opposed to well plates.[22] Following exposure to EtO/EtOH/
CO2 (Table 1), approximately 20 mg of microspheres (n = 3) were loaded into 1.5 mL
microcentrifuge tubes (Fisher Scientific). The total mass of TGF-β3 theoretically loaded in
each sample was 600 ng, whereas the total mass of BMP-2 theoretically loaded in each
sample was 1200 ng. The tubes were filled with 1.1 mL PBS and placed in an incubator at
37 °C with 5% CO2. The tubes were not agitated continuously, as this was most
representative of the microsphere environment in a scaffold formulation: static and in close
proximity to one another. At each sampling time point, the tubes were lightly inverted, then
centrifuged at 5,000 rpm for 30 seconds. A 1.0 mL sample of PBS surrounding the
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microspheres was removed from each tube and gently pipetted into a concentrated BSA-in-
PBS solution such that the final BSA concentration was 0.1% w/v. BSA was included as a
carrier protein to aid in the prevention of TGF-β3 and BMP-2 aggregation and to bind to
container surfaces during sampling and storage. The aliquots were split into two parts (one
for ELISA, one for cell culture) and frozen at −80 °C until study completion (Fig. 1B).
Sampling was done at 12 hours, then at 1, 2, 3, 5, 7, 10, 14, 18, 22, 26, 30, 34, 38, and 42
days. Release profiles were determined via sandwich ELISAs. Enzyme-linked
immunosorbent assay (ELISA) development kits for TGF-β3 and BMP-2 were purchased
from R&D Systems (Minneapolis, MN) and Peprotech, Inc., respectively. External
standardization was performed with each ELISA kit to account for discrepancies in
sensitivity to the E. coli derived proteins. Separate ELISAs confirmed that BSA use in
diluents did not inhibit protein detection. Protein release was represented as total mass and
percent (normalized to total protein released at 42 days).
2.9 Cell Seeding and Culture
Frozen hBMSCs at P1 (i.e., plated once) were thawed and plated at a density of 10,000 cells/
cm2 on tissue culture-treated well plates. The culture medium for hBMSCs consisted of
Dulbecco's Modified Eagle medium (DMEM; low glucose), 1% penicillin–streptomycin (P/
S), and 10% fetal bovine serum (FBS-MSC certified) (all from Invitrogen Life
Technologies, Carlsbad, CA). Cells were allowed to attach to the plates for 24 hours. At this
time (denoted as “Day 0”), the medium was refreshed, along with an additional growth
factor treatment. The growth factor treatments were the protein-containing supernatants
from the completed release study, administered daily for 12 days, corresponding to the first
12 release sampling intervals (30 days, ≥90% total protein released). During daily medium
refreshing and growth factor treatments, the volume ratio of medium to growth factor
aliquot was 1:1 to ensure cell viability (Fig. 1B). Negative and positive control groups were
also included. The negative control consisted of 0.1% BSA in PBS without protein.
2.10 Positive Control Selection for Cell Culture
The positive control concentration was derived from the average burst concentration
between microsphere groups for each protein formulation (Fig. 1C). Specifically, the
average burst concentration was calculated for each formulation (either TGF- β3, BMP-2, or
BMP-2 with HAp), rounded up to the nearest 10 ng/mL (Table 2), and then divided by 2 (to
allow for a 1:1 medium dilution with eluted protein samples). Positive control
concentrations were delivered to cells on a daily basis. Positive control samples were also
reconstituted in 0.1% BSA in PBS and subjected to one freeze-thaw cycle, just as release
supernatants.
2.11 Quantitative Polymerase Chain Reaction
In preparation for RT-PCR, samples (n = 3) at 0 and 12 days were first homogenized in 1
mL Trizol reagent (Invitrogen) and the RNA was isolated according to the manufacturer's
guidelines. Isolated RNA was cleaned with an RNeasy spin column method (Qiagen,
Valencia, CA) and converted to cDNA using a TaqMan High Capacity kit (Applied
Biosystems, Foster City, CA) in a BioRad ThermoCycler. TaqMan Gene expression assays
from Applied Biosystems for glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
Hs99999905_m1), bone gamma-carboxyglutamate protein (BGLAP, Osteocalcin,
Hs01587813_g1), collagen type I (COL1A1, Hs00164004_m1), runt-related transcription
factor 2 (RUNX2, Hs00231692_m1), aggrecan (ACAN, Hs00202971_m1), collagen type II,
(COL2A1, Hs00156568_m1), and sex determining region Y-box 9 (SOX9,
Hs00165814_m1) were used in conjunction with an Applied Biosystems 7500 Fast Real-
time PCR System. A 2−ΔΔCt method was used to evaluate the relative level of expression for
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each target gene.[37] For quantification, the negative control (at day 0) constructs were
designated as a calibrator group, and GAPDH expression as an endogenous control.
2.12 Statistical Analyses
Statistical analyses were performed using a single factor analysis of variance (ANOVA)
followed by a Tukey's Honestly Significant Difference post hoc test in PASW 18.0 software
(SPSS Incorporated, Chicago, IL), when significance was detected below the p = 0.05 value.
All quantitative results (numerical values and representative diagrams) are expressed as the
average ± standard deviation.
3. RESULTS
3.1 Glass Transition Temperatures
Glass transition temperatures for PLGA/HAp composite microspheres were about 10 °C
lower than pure PLGA microspheres following EtO + CO2 (p <0.05), EtO + EtOH (p <
0.05), and EtOH only (p < 0.005) treatments, whereas there was no statistically significant
difference in Tg between PLGA and PLGA/HAp composite microspheres that received only
EtO exposure. Similarly, there were no statistically significant differences among Tg in
PLGA only microspheres, or among Tg PLGA/HAp composite microspheres (Fig. 2).
3.2 TGF-β3 Release from PLGA Microspheres
Total protein release from microspheres loaded with TGF-β3 was markedly different among
experimental groups (data not shown). Microspheres with only EtO exposure demonstrated
a release of ~175 ng of TGF-β3 by 7 days, with another small burst at 14 days. Net release
leveled off afterward, with a small burst at 42 days. The release behavior for microspheres
treated with EtO/CO2 was similar, with a maximum of ~150 ng of TGF-β3 by 42 days. For
microsphere groups treated with EtOH, however, the total amount of TGF-β3 liberated was
almost 3 times as much by 42 days. The release behavior for EtO/EtOH and EtOH only-
treated groups exhibited more distinct third release phases at approximately 21 days, with
~400 and ~350 ng delivered by 42 days. The standard deviations related to groups treated
with EtOH were considerably larger than the EtO and EtO/CO2 groups. In all of the groups,
40% of TGF-β3 was released by 24 hours, and at least 60% by 14 days (Fig. 3).
3.3 BMP-2 Release from PLGA Microspheres
Net protein delivery from microsphere groups loaded with BMP-2 followed similar patterns
to those loaded with TGF-β3 (data not shown). The total mass of BMP-2 liberated in the
EtO-treated group was greater than the EtO/CO2 group (~700 ng versus ~400 ng by 42
days), with the EtO-treated group exhibiting a third phase of release at 21 days. For
microsphere groups treated with EtO/EtOH and EtOH only, the total amounts of BMP-2
delivered were ~950 and ~800 ng, respectively. The initial burst behavior for EtOH-treated
groups was dissimilar to EtO and EtO/CO2 groups. Specifically, for EtO and EtO/CO2
microspheres, ~80% of BMP-2 had been released within 7 days, whereas only ~50% of the
protein was delivered by the same time in EtOH-treated groups (Fig. 3). As with TGF-β3,
the standard deviations in EtOH-treated groups were relatively large compared to the other
groups.
3.4 BMP-2 Release from PLGA/HAp Microspheres
Total BMP-2 release from composite PLGA/HAp microspheres was far less than that of
BMP-2 from non-composite microspheres, with as little as ~150 ng from EtO-treated
groups, and as much as ~300 ng from EtO/CO2-treated groups (data not shown). A third
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phase of release was not observed for any of the composite PLGA/HAp groups. The net
mass and percent of protein liberated was essentially unchanged after 21 days (Fig. 3).
3.5 Bioactivity of TGF-β3 from PLGA Microspheres
For TGF-β3-stimulated hBMSCs, expression of aggrecan, collagen II, and Sox9 was
monitored at 0 and 12 days. For aggrecan (Fig. 4A), only the EtOH-treated group
demonstrated a statistically significant increase in gene expression relative to the day 0 value
(p < 0.05). For collagen II expression (Fig. 4B), only the negative control was shown to have
a significantly increased expression at 12 days compared to the day 0 value (p < 0.05). There
were no statistically significant differences among treatment groups at 12 days for Aggrecan
or Collagen II. With regard to Sox9 expression (Fig. 4C), only the positive control was
statistically different from the negative control (lower) at 12 days (p < 0.05), but positive
control expression was not significantly different from the experimental groups.
3.6 Bioactivity of BMP-2 from PLGA Particles
For BMP-2-stimulated hBMSCs, expression of osteocalcin, collagen I, and Runx2 was
monitored at 0 and 12 days. Expression of osteocalcin (Fig. 5A) was decreased for all
samples at 12 days relative to the day 0 value (p < 0.0005). Only the EtO-treated group was
found to be significantly greater than the positive control (p < 0.05). For collagen I
expression (Fig. 5B), only the EtO and EtO/CO2 groups were found to have increased
expression relative to the day 0 value (p < 0.05). All of the groups except for the positive
control were found to have increased Runx2 expression (Fig. 5C) relative to the day 0 value
(p < 0.01). The negative control and experimental groups had a significantly increased
expression of Runx2 compared to the positive control at day 12 (p < 0.005).
3.7 Bioactivity of BMP-2 from PLGA/HAp Particles
For BMP-2-stimulated hBMSCs (from HAp microspheres), expression of osteocalcin,
collagen I, and Runx2 was monitored at 0 and 12 days. Osteocalcin expression (Fig. 6A)
was decreased at 12 days, compared to the day 0 value, in groups treated with BMP-2
released from composite microspheres (p < 0.0005), but expression was not significantly
different among experimental and control groups at 12 days. Collagen I expression (Fig. 6B)
in the negative control and experimental groups was less than the positive control at 12 days
(p < 0.001). Notably, expression of BMP-2 in the positive control was also greater than day
0 (p < 0.0005). Runx2 expression (Fig. 6C) was similar between the positive and negative
control groups at 12 days, and expression in these groups was also greater than the day 0
value (p < 0.0005). All four experimental groups had decreased Runx2 expression at day 12
compared to the positive and negative controls (p < 0.0005).
4. DISCUSSION
This was the first study to investigate the release and relative bioactivity of TGF-β3 and
BMP-2 following various processing and sterilization factors used in microsphere-based
scaffold technology.[23, 25, 26] The results have implications on the efficacy of growth
factor incorporation for stem cell differentiation in a 3-D scaffolding environment.
Glass transition temperature data provided a clear distinction between microspheres
containing HAp and those without. A reason for all groups with HAp having a decrease in
Tg is not readily discernable, but may be due to HAp disrupting the polymer network within
the microsphere, thus enabling more efficient penetration of CO2 and EtOH during the
solvent treatments. Even though a previous investigation found that a 50 minute ethanol
exposure lowered the glass transition temperature (Tg) of a ~50 kDa 50:50 PLGA, [25] the
current study demonstrated no statistically significant differences in Tg between EtOH-
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treated groups (both PLGA and PLGA/HAp composite) and their controls. The discrepancy
may have been due to differing molecular weights.
During protein release, a noticeable difference occurred with regard to whether
microspheres were treated with EtOH. The fact that EtOH-treated groups released more
TGF-β3 and BMP-2 from PLGA microspheres suggested that perhaps a pre-solubilization of
the polymer allowed for diffusion of protein from the innermost layers of the microspheres
toward the perimeter. When placed in release medium, the outermost layer of the
microspheres may have been “primed” with protein, hence the large amount dumped in the
first week of release. Such a phenomenon came with higher variability. EtOH exposure as a
co-solvent has been shown to adversely affect drug loading and simultaneously increase the
“burst” release from PLGA microparticles by concentrating drug at the surface of the
vehicle.[38] Such an increased mass released with EtOH-exposure, or any treatment, did not
occur with composite PLGA/HAp microspheres. With Tg data supporting a disruption in the
polymer network from mineral incorporation, a low protein release was more likely a
consequence of either a poor entrapped mass of protein during fabrication. Alternatively, the
physicochemical properties of HAp might have created an environment that hindered protein
liberation from the bulk of the microsphere, physically or chemically,[39-42] which has
been seen before with BMP-2.[43]
Similarly to HAp formulations, CO2 treatments also leveled off in net mass released by 21
days, and did not exhibit a third phase of release. The absence of a third phase is
contradictory to theoretical macromolecule release profiles from microspheres,[44] which
was most aptly demonstrated by the profile for TGF-β3 EtO/EtOH group. An absence of this
phase may have been indicative of protein retention inside the vehicle.[39-42] The mass of
released BMP-2 relative to TGF-β3 was in approximate correspondence with the loading
ratio of 2:1 (60 ng BMP-2/mg or and 30 ng TGF-β3/mg) or the microsphere formulations,
even though the shape of the release for each of these proteins was somewhat different.
Different release profile shapes may indicate that although the proteins are approximately
the same size, their diffusion from the microsphere core was altered due to the
environmental factors. Overall, however, using the simple estimate that equilibrium is
reached when the Fourier number for diffusion is approximately equal to unity, D*t/L2≈1,
the magnitude of the diffusion coefficients for TGF-β3 and BMP-2 can be estimated.[45]
Here, L represents the characteristic length of the microspheres (the radius, ~125 μm), D is
the diffusion coefficient (cm2/sec), and t is the characteristic timescale (about 7 days to
reach the lag phase in release). This yields a diffusion coefficient of ~3 x 10-10 cm2/sec,
which is on the order of typical diffusion coefficients of proteins in polymers.[46-49] It
should be noted that some of the solvent treatments utilized in this study were polar
molecules (EtO and EtOH), which might have disrupted protein conformation or unfolding,
leading to aggregation, which would also affect diffusivity of the macromolecules from the
vehicles. Future studies should consider the extent of protein aggregation due to EtO and
EtOH exposure.
In addition to atypical behavior in the release profiles, cell differentiation studies indicated
that the released proteins might have exhibited a diminished bioactivity. To put bioactivity
into context, both positive and negative controls were included for each type of formulation.
Aggrecan expression was similar between virtually all of the groups at 12 days, which only
demonstrated that perhaps TGF-β3 did not stimulate aggrecan expression in the prescribed
experimental conditions. Collagen II expression, however, was dramatically increased at 12
days in the negative control compared to the day 0 value, lending to the notion that TGF-β3
in the treatment groups had a similar effect as TGF-β3 in the positive control. The ability of
the released proteins to affect Sox9 expression was ambiguous. BMP-2 from non-composite
microsphere formulations showed a similar performance to the positive control with regard
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to osteocalcin and collagen I expressions, but showed a distinctly different performance
from the positive control with respect to Runx2 expression. A similar confounding result
was seen with regard to Runx2 expression from composite-HAp microspheres, where
experimental expression was different from both positive and negative controls. It is difficult
to identify circumstances, however, when the experimental treatment groups would alter
protein structure or function in such a way that selectively affects the expression of certain
genes. Likewise, it is important to identify that gene expression not readily affected by the
treatment groups does not necessarily mean inactive proteins, but potentially protein
concentrations that were not ideal. Coupled with Tg data, some experimental groups with
HAp may have had lower entrapped protein concentrations after microsphere drying.
Additionally, positive control concentrations were representative of the average
experimental concentrations, and were provided continually throughout culture. The
experimental design attempted to mitigate this problem by using a minimal medium:release
aliquot dilution of 1:1. Thus, while a perfectly ideal positive control is not realistic, an effort
was made to provide a reasonable value to serve the purpose of placing experimental group
results in perspective.
Other factors that could have affected gene expression relate to the components of the
release supernatants during cell feeding. Specifically, release samples contained the acidic
breakdown products of PLGA, lactic acid and glycolic acid, which was evidenced by
medium color change during feedings, and would certainly differ from in vivo conditions,
where buffering and removal would in part contribute to differences. During breakdown, the
pH within each microsphere can become as low as 1.5.[50] This acidic microenvironment
might have been an influence on selective gene expression or overall bioactivity of TGF-β3
or BMP-2. Similarly, in groups with PLGA/HAp microspheres, a small amount of HAp was
certainly present in the release medium as well, which also might have affected gene
expression. Since PLGA degradation is highly acidic,[50, 51] using other buffers such as
calcium carbonate or sodium bicarbonate may serve to mitigate acid-related adverse effects.
Lastly, although ELISA cannot be taken as an absolute indication of bioactivity, it is an
indication that much of the structural integrity of the proteins was retained for at least non-
composite microspheres.
From the perspective of current techniques for making microsphere-based scaffolds, it
seems as though the approach of EtOH treatment[22-25] for microsphere sintering delivered
the most protein over the course of 6 weeks, as opposed to CO2 exposure.[26] While the
variability of BMP-2 and TGF-β3 delivery in EtOH formulations was larger, this might
perhaps be a small sacrifice compared to losing a considerable fraction of protein to
encapsulation or long-term retention and aggregation inside the vehicle. In addition, there is
currently no definitive indication that EtOH sintering, or any treatment, is detrimental to
cellular stimulation, as gene expression is only a “snapshot” of fluctuating transcription and
translation of proteins relevant to differentiation. In addition, changing gene expression may
also be due to other factors not explicitly targeted within the scope of this manuscript, such
as response to PLGA attachment, HAp presence, or cell feeding conditions. For the purposes
of sterilization, there was not enough evidence to conclude that EtO drastically affected
protein liberation or bioactivity under the experimental conditions, which was supported by
Tg and RT-PCR data. For all formulations, however, the timeline of growth factor release
may not necessarily correspond to cellular differentiation requirements in vivo. The release
pattern may also not be commensurate with local and systemic immune responses during the
earliest stages of wound healing, as this might adversely affect the overall efficacy of protein
delivery in several ways.[27] The duration of release, however, was favorable in the context
of osteochondral wound healing, as this process requires great lengths of time to complete in
vivo.
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Future work should focus on developing methods to properly quantify the actual amount of
entrapped protein, the physical protein distribution within the microsphere formulations,
whether solvent treatments lend to protein aggregation, and physical protein-HAp
interactions. The aforementioned studies should provide insight into questions whether HAp
inhibits BMP-2 loading during fabrication, as supported by Tg data, and whether including
HAp in formulations provides a regenerative benefit over only BMP-2 incorporation. Cell
differentiation studies with more frequent time points might also further contextualize the
bioactivity of the proteins. In addition, methods to remove polymer byproducts or HAp
particles from the release supernatant, or add these factors to positive control groups, will
also give a more accurate reproduction of the release medium and protein microenvironment
during breakdown of the particles in vitro.
5. CONCLUSIONS
This was the first study to investigate several high-interest processing conditions on the
release and relative bioactivity of growth factors that are used in a continuously-graded
scaffold technology.[22-25] Release profiles indicated that microspheres released protein
with a diffusional profile during the first week, and in some instances, provided a third phase
of release near 3 weeks. Formulations that were exposed to EtOH generally released more
protein, and had larger variations in release profiles. Formulations with HAp released less
protein, which may have been related to a poor initial protein entrapment, as supported by
Tg data. Cell bioactivity assays indicated that in some instances, the experimental groups
had an effect on hBMSC gene expression, but optimal concentrations may not have been
employed with the current experimental design. In addition, the breakdown products of
microspheres may have affected cell stimulation under the prescribed experimental
conditions. The overall results indicated, however, that protein release from microspheres
exposed to key processing and sterilization methods required to formulate microsphere-
based scaffolds, was entirely feasible with PLGA or PLGA/HAp formulations, and
especially those treated with EtOH during the sintering step, which makes this technology a
candidate for scaffolds with continuous growth factor[23, 25] and material composition and
stiffness[24] gradients.
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• Protein-loaded PLGA microspheres were subjected to post processing
conditions.
• Released protein was used in cell stimulation studies.
• Ethanol exposure was found to increase amount of released protein.
• Hydroxyapatite and carbon dioxide decreased amount of released protein.
• Hydroxyapatite presence decreased the glass transition temperature of
microspheres.
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Particle fabrication and release experiment. (A) Precision particle fabrication apparatus
made microparticles with high monodispersity. (B) At each sampling time point, supernatant
was mixed with a concentrated BSA solution, split into two aliquots, and used in ELISA and
cell stimulation. (C) The positive control protein concentration was defined as the average
concentration during the burst release for TGF-β3, BMP-2, or BMP-2 from PLGA/HAp
composite microspheres. The positive control concentration was provided to hBMSCs daily
for 12 days, whereas treatment aliquots contained decreasing concentrations with time.
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Glass Transition Temperature (Tg). Glass transition temperatures for PLGA/HAp composite
microspheres were lower than PLGA only microspheres following EtO + CO2, EtO + EtOH,
and EtOH only treatments, whereas there was no statistically significant difference in Tg
between PLGA and PLGA/HAp composite microspheres that received only EtO exposure.
Similarly, there were no statistically significant differences among Tg in PLGA only
microspheres, or among Tg PLGA/HAp composite microspheres. All values are expressed
as the average ± standard deviation (n = 3), p < 0.05, * = statistically significant difference
from the control at that time point.
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Percent protein released. Results demonstrated that EtOH-treated microspheres without HAp
released a lower percentage of protein than control or CO2-treated groups before 7 days, but
ultimately delivered a larger percentage in the remaining 35 days. The shape of the release
profiles was similar between all formulations, with ~90% of the protein being released by 30
days. Data is represented as percentage mass released ± standard deviation. The percent
released was calculated relative to the total mass liberated at 42 days. All values are
expressed as the average ± standard deviation (n = 3), p < 0.05, @ = statistically significant
difference from week 0 value, # = statistically significant difference from the negative
control at that time point, and * = statistically significant difference from the positive control
at that time point.
Dormer et al. Page 18














Chondrogenic gene expression of hBMSCs. For cells treated with TGF-β3 groups. (A)
Aggrecan expression demonstrated that treatment groups performed similar to both the
positive and negative controls. (B) Collagen II expression showed treatment groups
performed similar to the positive control. (C) Sox9 expression demonstrated that
experimental groups performed similar to negative control, but were not different from the
positive control. All values are expressed as the average ± standard deviation (n = 3), p <
0.05, @ = statistically significant difference from week 0 value, # = statistically significant
difference from the negative control at that time point, and * = statistically significant
difference from the positive control at that time point.
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Osteogenic gene expression of hBMSCs for BMP-2. For cells treated with BMP-2 groups.
(A) Osteocalcin and (B) Collagen I expression demonstrated that treatment groups behaved
similar to both the positive and negative controls. (C) Runx2 expression demonstrated that
experimental groups performed similar to negative control. All values are expressed as the
average ± standard deviation (n = 3), p < 0.05, @ = statistically significant difference from
week 0 value, # = statistically significant difference from the negative control at that time
point, and * = statistically significant difference from the positive control at that time point.
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Osteogenic gene expression of hBMSCs for BMP-2/HAp. For cells treated with BMP-2
from HAp composite scaffolds. (A) Osteocalcin expression demonstrated that treatment
groups performed similar to both the positive and negative controls. (B) Collagen I
expression shows treatment groups behaved similarly to the negative control. (C) Runx2
expression demonstrated that experimental groups had expression that was unlike either
positive or negative controls. All values are expressed as the average ± standard deviation (n
= 3), p < 0.05, @ = statistically significant difference from week 0 value, # = statistically
significant difference from the negative control at that time point, and * = statistically
significant difference from the positive control at that time point.
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Table 1
Experimental reatment conditions for protein-loaded microspheres.
Formulation Treatment EtOH or CO2 Conditions
EtO -
















BMP-2 + HAp EtO + CO2
EtO + EtOH
EtOH
25 bar, 60 minutes
90 minutes
90 minutes
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Table 2
Selection of positive control growth factor concentrations for cell stimulation studies.
Formulation Treatment Burst (ng/mL) Average (ng/mL) Positive (ng/mL)
EtO 52
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